Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2017

Jan 3, 2017

Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Nov 7, 2016

Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 – A Cancer Cell Specific Anticancer Agent

Oct 31, 2016

Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of Docetaxel for the Targeted Treatment of Solid Tumors

Oct 26, 2016

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress

Oct 10, 2016

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress

Oct 4, 2016

Rexahn Announces $6 Million Registered Direct Offering

Sep 14, 2016

Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer

Sep 12, 2016

Rexahn Pharmaceuticals to Present at 18th Annual Rodman & Renshaw  Global Investment Conference on September 12, 2016

Sep 7, 2016

Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial and Operational Results

Aug 8, 2016